BelliniCDonariniGPaladiniD. Etiology of non-immune hydrops fetalis: an update. Am J Med Genet A. 2015;167:1082-1088.
2.
ZipurskyARoseTSkidmoreMThornerPDoyleJ. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol. 1996;53:81-87.
3.
SorrellADAlonzoTAHildenJM. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children’s Oncology Group trial A2971: a report from the Children’s Oncology Group. Cancer. 2012;118:4806-4814.
4.
GamisASAlonzoTAGerbingRB. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752-6759.
5.
GamisASSmithFO. Transient myeloproliferative disorder in children with Down syndrome: Clarity to this enigmatic disorder. Br J Haematol. 2012;159:277-287.
6.
HonKLeungT. Transient myeloproliferative disorder and non-immune hydrops fetalis in a neonate with trisomy 21. Hong Kong Med J. 2014;20:78.e3-e4.
7.
AnukDTarcanAAliogluB. Hydrops fetalis in a neonate with Down syndrome, transient myeloproliferative disorder and hepatic fibrosis. Fetal Pediatr Pathol. 2007;26:223-228.
8.
HayasakaIChoKMoriokaK. Exchange transfusion in patients with Down syndrome and severe transient leukemia. Pediatr Int. 2015;57:620-625.
9.
LichtmanMARoweJM. Hyperleukocytic leukemias: rheological, clinical and therapeutic considerations. Blood. 1982;60:279-283.
10.
StuckiARivierASGikicMMonaiNSchapiraMSpertiniO. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood. 2001;97:2121-2129.
